Human protective antibodies for use against H7N9 influenza virus

This technology describes human monoclonal antibodies derived from the B cells of a case of zoonotic avian influenza virus H7N9 to treat or prevent H7N9 infections.

Unmet Need: Direct method for the prevention and treatment of H7N9

H7N9 infection can cause viral pneumonia and progress to acute respiratory distress, especially in older patients with underlying comorbidities. There is currently no direct antiviral for the treatment of H7N9, with inhibitors that are effective against other viral strains as the current treatment method for H7N9 patients.

The Technology: Human monoclonal antibodies for the treatment and prevention of H7N9

This technology describes human monoclonal antibodies derived from the B cells of a resolving case of H7N9. These antibodies bind specifically to the hemagglutinin (A) of the H7N9 virus to block viral entry into cells. A series of antibodies were shown to directly neutralize the H7N9 virus in vitro and confer protection when given prophylactically.

This technology has been validated in vivo with murine viral challenges.

Applications:

• Post-exposure treatment and prophylaxis for H7N9
• Research tool to investigate H7N9 viral entry
• H7N9 viral titer quantification
• Diagnostic method for identifying H7N9

Advantages:

• Binds specifically to the hemagglutinin (HA) of the H7N9 virus for targeted treatment
• Potent neutralizing activity against H7N9 in vitro
• Confers protection against H7N9 infection when administered prophylactically in mice

Lead Inventor:

Xueling Wu, M.D., Ph.D.

Patent Information:

Patent Pending

Related Publications:

• Jia M, Zhao H, Morano NC, Lu H, Lui YM, Du H, Becker JE, Yuen KY, Ho DD, Kwong PD, Shapiro L. Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head. Nature Communications. 2024 May 27;15(1):4505.

Tech Ventures Reference:

• IR CU23380

• Licensing Contact: Kristin Neuman